Compare Sana Biotechnology Inc (SANA) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while iShares 10 20 Year Treasury Bond ETF trades at $96.56. The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SANA | TLH | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Fixed Income |
52-Week High | $5.92 | $105.36 |
52-Week Low | $2.68 | $96.39 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
TLH trades at $96.57, up 0.19% today, with a bearish technical signal from moving averages and neutral oscillators. Recent dividends include $0.38 (July 2026), $0.36 (June 2026), and $0.41 (May 2026). Key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity. Support and resistance cluster near $96-$97, indicating tight price consolidation amid weak momentum.
The outlook is cautious due to missing financial metrics and bearish technicals. Risks include reliance on dividend stability and macroeconomic pressures from rising yields. Opportunities may arise if fundamentals improve, but current data suggests limited upside without clearer earnings visibility or positive analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
